Dev Karan1, Seema Dubey1, Lucia Pirisi2, Alexis Nagel3, Ivett Pina3, Yeun-Mun Choo4, Mark T Hamann3. 1. Department of Pathology, MCW Cancer Center and Prostate Cancer Center of Excellence , Medical College of Wisconsin , 8701 Watertown Plank Road , Milwaukee , Wisconsin , United States. 2. Department of Pathology, Microbiology and Immunology , University of South Carolina School of Medicine , Columbia , South Carolina , United States. 3. Department of Drug Discovery and Biomedical Sciences , Medical University of South Carolina , Charleston , South Carolina , United States. 4. Department of Chemistry , University of Malaya , Kuala Lumpur , Malaysia.
Abstract
Natural products remain an important source of drug leads covering unique chemical space and providing significant therapeutic value for the control of cancer and infectious diseases resistant to current drugs. Here, we determined the antiproliferative activity of a natural product manzamine A (1) from an Indo-Pacific sponge following various in vitro cellular assays targeting cervical cancer (C33A, HeLa, SiHa, and CaSki). Our data demonstrated the antiproliferative effects of 1 at relatively low and non-cytotoxic concentrations (up to 4 μM). Mechanistic investigations confirmed that 1 blocked cell cycle progression in SiHa and CaSki cells at G1/S phase and regulated cell cycle-related genes, including restoration of p21 and p53 expression. In apoptotic assays, HeLa cells showed the highest sensitivity to 1 as compared to other cell types (C33A, SiHa, and CaSki). Interestingly, 1 decreased the levels of the oncoprotein SIX1, which is associated with oncogenesis in cervical cancer. To further investigate the structure-activity relationship among manzamine A (1) class with potential antiproliferative activity, molecular networking facilitated the efficient identification, dereplication, and assignment of structures from the manzamine class and revealed the significant potential in the design of optimized molecules for the treatment of cervical cancer. These data suggest that this sponge-derived natural product class warrants further attention regarding the design and development of novel manzamine analogues, which may be efficacious for preventive and therapeutic treatment of cancer. Additionally, this study reveals the significance of protecting fragile marine ecosystems from climate change-induced loss of species diversity.
Natural products remain an important source of drug leads covering unique chemical space and providing significant therapeutic value for the control of cancer and infectious diseases resistant to current drugs. Here, we determined the antiproliferative activity of a natural product manzamine A (1) from an Indo-Pacific sponge following various in vitro cellular assays targeting cervical cancer (C33A, HeLa, SiHa, and CaSki). Our data demonstrated the antiproliferative effects of 1 at relatively low and non-cytotoxic concentrations (up to 4 μM). Mechanistic investigations confirmed that 1 blocked cell cycle progression in SiHa and CaSki cells at G1/S phase and regulated cell cycle-related genes, including restoration of p21 and p53 expression. In apoptotic assays, HeLa cells showed the highest sensitivity to 1 as compared to other cell types (C33A, SiHa, and CaSki). Interestingly, 1 decreased the levels of the oncoprotein SIX1, which is associated with oncogenesis in cervical cancer. To further investigate the structure-activity relationship among manzamine A (1) class with potential antiproliferative activity, molecular networking facilitated the efficient identification, dereplication, and assignment of structures from the manzamine class and revealed the significant potential in the design of optimized molecules for the treatment of cervical cancer. These data suggest that this sponge-derived natural product class warrants further attention regarding the design and development of novel manzamine analogues, which may be efficacious for preventive and therapeutic treatment of cancer. Additionally, this study reveals the significance of protecting fragile marine ecosystems from climate change-induced loss of species diversity.
Natural products
have a long
history of use in the treatment of various diseases including cancer.
The primary sources of successful natural product cancer therapeutics
have been from microbes and plants from the environment. In fact,
more than 49% of currently used anticancer agents are either natural
products or directly derived from natural products.[1] Marine natural products from animals, plants, and bacteria
continue to provide a highly productive resource for the discovery
and development of new, innovative disease treatments with novel mechanisms
of action.[2] The marine environment is unique
with regard to the high degree of competition among species, and the
kinetics of metabolite transport in densely populated aqueous environments
make marine organisms a rich source of structurally diverse and complex,
bioactive natural products.[3] Sessile marine
organisms such as sponges are particularly rich in this regard, as
they depend solely on either physical or chemical mechanisms to escape
predation. Marine-derived bioactive terpenes alkaloids, macrolides,
and other compounds isolated from aquatic fungi, cyanobacteria, algae,
sponges, and tunicates, have all been found to exhibit various anticancer
activities.[4−7]Here, we studied the effect of a marine sponge product, namely,
manzamine A (1), on cervical cancer cells. Cervical squamous
dysplasia and cancer are due to infectious agents such as human papilloma
virus (HPV), particularly the HPV types 16 and 18, which collectively
account for an estimated 70% of all cervical cancer cases. For cervical
cancer prevention, HPV vaccines (Gardasil, Gardasil 9, and Cervarix)
protect against cervical infection with the HPV types included in
the vaccines in women not previously exposed to HPV infection.[8−10] However, HPV is a prophylactic vaccine, which must be introduced
at a young age prior to HPV infection. Over 50% of women diagnosed
with cervical cancer have stage II–IV disease and require combination
of chemotherapy and radiation as their primary treatment.[11] As proven clinically, these treatment modalities
are associated with long-term side effects that significantly affect
quality of life. Therefore, there is a continuous need to develop
more effective therapies that can cure localized tumors and prevent
progression and metastasis of cervical cancer.The manzaminealkaloids are isolated from Indo-Pacific sponges
and represent a group of complex β-carboline alkaloids characterized
by a unique nitrogen-containing polycyclic system. While some 80 manzamine
analogues have been reported over the past two decades, it is likely
that many more remain to be characterized and prepared through medicinal
chemistry studies. This class of alkaloids has been previously reported
to possess a wide variety of biological activity, and 1 has emerged as a promising drug candidate for the treatment of multiple
disease conditions.[12−14] However, studies examining the effect of 1 in cancer are very limited. In this study, we demonstrate that manzamine
A (1) inhibits the growth of cervical cancer cells, inducing
cell cycle arrest and stimulating apoptosis-related molecular pathways.
We employed molecular networking (MolN) to facilitate the design of
novel analogues that may harbor improved potential therapeutic activity
against cervical cancer and other diseases. Furthermore, three novel
manzamine analogues were discovered through mass spectrometry (MS)-based
MolN, providing new directions for the investigation of manzamine
A (1) and its mechanisms for the prevention or treatment
of cervical cancer.
Results and Discussion
Molecular Networking (MolN)
Facilitates Identification of Novel
Manzamine A (1) Analogues
The discovery of natural product
therapeutic leads continues to be greatly facilitated by highly sensitive
mass spectrometry-based analysis that allows a higher-order view of
metabolic diversity present within a biological sample. Posing a considerable
challenge however is the streamlining of high-content MS data for
identification of new mass species with potentially therapeutic properties.
Here, we employed MoIN to aid in the discovery of new manzamine alkaloids
based on comparisons between MS/MS-derived data with available literature.
Untargeted liquid chromatography (LC)-MS/MS analysis was performed
on dried total alkaloid and fractionated extracts previously prepared
from the Indonesian sponge Acanthostrongylophora sp.
The presence of manzamine constituents manzamine A (1), manzamine D (2), manzamine F (3), 8-hydroxymanzamine
A (4), ircinal A (5), and ircinol A (6) were previously detected by thin-layer chromatography and
NMR.[12,15] Samples were analyzed by LC-ESI-MS/MS (ESI
= electrospray ionization) using an Impact II qTOF (Bruker) and spectral
data networked using the GNPS open-source spectral networking script
(Figure ).[16] Putative molecular formulas were generated for
all features in 1 network (Supporting Information Table 1) based upon high-resolution (HRMS) data
(not shown) and their relationship to known major and minor manzamine
constituents (manzamine A (1), [M + H]+ 549.358 550 m/z, Δ = 0.2 ppm; manzamine E, [M
+ H]+ 565.353 703 m/z, Δ = 0.1 ppm; manzamine F (3), [M + H]+ 581.348 918 m/z, Δ
= −0.5 ppm), as well as ircinal A (5) [M + H]+ 411.300 598, Δ = 0.0 ppm) and ircinol A (6) ([M + H]+ 413.316 214 m/z; Δ = 0.1 ppm), which served as reference
mass features. Fourteen mass features were assigned that, to our knowledge,
do not correspond to any known, naturally occurring 1 derivative that could be determined through literature or database
searching.
Figure 1
MolN analysis of sponge-derived alkaloids, with mass features color-coded
by mass range (yellow = 400–500 m/z; blue = 500–600 m/z; green = 600–700 m/z. The
confirmed structures of 1, 3, 4, 5, and manzamine E were completed using 1H NMR and MS/MS. The chemical structures of 1 and 4, the most abundant metabolites, were highlighted on blue
boxes, while those of 3, 5, and manzamine
E were on green boxes. *Two synthetic manzamine derivatives were used
as control, compound 1, and compound 2, represented at the right of
the figure. A full list of node retention times, exact and accurate
mass measurements, and molecular formulas are represented in Supporting Information Table 1.
MolN analysis of sponge-derived alkaloids, with mass features color-coded
by mass range (yellow = 400–500 m/z; blue = 500–600 m/z; green = 600–700 m/z. The
confirmed structures of 1, 3, 4, 5, and manzamine E were completed using 1H NMR and MS/MS. The chemical structures of 1 and 4, the most abundant metabolites, were highlighted on blue
boxes, while those of 3, 5, and manzamine
E were on green boxes. *Two synthetic manzamine derivatives were used
as control, compound 1, and compound 2, represented at the right of
the figure. A full list of node retention times, exact and accurate
mass measurements, and molecular formulas are represented in Supporting Information Table 1.
Biological Effect of Marine Sponge Natural Product Manzamine
A (1) on Cervical Cancer Cell Growth
We determined the biological
activity of 1 on cervical cancer cells C33A (HPV-negative),
HeLa, SiHa, and CaSki (HPV16/18-positive) using a wide range of concentrations
(0–40 μM) at different time points (24, 48, and 72 h).
The CellTiter-Glo cell viability assay determined the cell viability
based on metabolically active cells producing adenosine triphosphate
(ATP) in the cell culture. The cell viability assay showed that C33A
and HeLa cells were more sensitive to (1) with the half
maximal inhibitory concentration (IC50) values of 2.1 and
4.0 μM at 48 h and values of 1.6 and 5.3 μM at 72 h as
compared to SiHa and CaSki cells. However, the CaSki cells were least
sensitive to (1) with IC50 values of 19.9
and 9.4 μM at 48 and 72 h, respectively (Figure ).
Figure 2
Biological effects of manzamine A (1) on cell viability
of cervical cancer cell lines (C33A, HeLa, SiHa, and CaSki). Twenty
thousand (2 × 104) cells were seeded in 96-well plates
and treated with a wide range from 1 to 40 μM concentration
of 1 for three time points (24, 48, and 72 h). The experiment
was repeated at least three times in quadruplicate from different
cell preparations with similar results. Percent viable cells were
used to calculate IC50 values and are shown in the inset
for all the cell lines at their respective time-points. The percent
viability values represent mean ± SEM.
Biological effects of manzamine A (1) on cell viability
of cervical cancer cell lines (C33A, HeLa, SiHa, and CaSki). Twenty
thousand (2 × 104) cells were seeded in 96-well plates
and treated with a wide range from 1 to 40 μM concentration
of 1 for three time points (24, 48, and 72 h). The experiment
was repeated at least three times in quadruplicate from different
cell preparations with similar results. Percent viable cells were
used to calculate IC50 values and are shown in the inset
for all the cell lines at their respective time-points. The percent
viability values represent mean ± SEM.To maintain the treatment uniformity across the cell lines, we
selected optimal dose concentration from 1 to 4 μM and treated
C33A, HeLa, SiHa, and CaSki cell lines. The cell-growth kinetics study
showed that 1 significantly inhibited cervical cancer
cell proliferation in a time- and dose-dependent manner as compared
to vehicle dimethyl sulfoxide (DMSO) control. This antiproliferation
cancer cell activity was further supported by the colony formation
assays, where 2 and 4 μM of manzamine A (1) inhibited
the cell growth demonstrating a sustained, long-term ability of 1 to suppress cervical cancer cell growth (Supporting Information Figure 1).On the basis of MoIN,
the additional manzamine-related compounds
such as manzamine D (2), manzamine F (3),
8-hydroxymanzamine A (4), and ircinal A (5) were tested for their biological activities targeting cervical
cancer cell lines (SiHa and CaSki). Manzamine D (2), 3, and 5 did not reveal any effect on cervical
cancer cell growth; however, compound 4 showed inhibition
of both SiHa and CaSki cells (Supporting Information Figure 2). Since 1 and 4 exhibited
antiproliferation of cancer cells, we further tested the effect of
these two analogues on normal human keratinocytes (HKc). On the one
hand, we observed that the cell-growth kinetics of the normal HKc
treated with 8-hydroxymanzamine A (4) at 4 μM concentration
was inhibited significantly (p = 0.0022 at 48 h and p = 0.0004 at 72 h) as compared to DMSO control. On the
other hand, manzamine A (1) showed no adverse effect
on normal HKc (Supporting Information Figure 3). These data suggest that compound 4 could be toxic
to human normal cells, while 1 is non-cytotoxic.Several groups have been pushing the boundaries of existing MolN
applications to expand their utility for natural product dereplication.
Notable efforts in this arena have been led by the lab of Crawford,
who has employed MolN and bioinformatics-guided isotopic labeling
to characterize elusive structural characteristics of the unstable
and genotoxic E. coli-derived colibactin class that
plays a role in colorectal cancer pathogenesis.[17,18] However, despite its potential utility, only a small number of studies
have exploited MolN as a tool to expedite the discovery and evaluation
of new druglike small-molecule natural products. Our networking results
also support MolN as a valuable workflow component for the discovery
of new manzamine lead molecules. MS-based MolN analysis facilitated
the identification of putative manzamine A (1)-related
structures that would have been challenging to identify using only
MS information. Interestingly, two of these compounds contain modifications
at the β-carboline moiety, a chemical group that has previously
been shown to be important to 1 bioactivity and mechanism
of action. Manzamine A (1)cytotoxicity has been linked
to β-carboline-mediated DNA intercalation in the major groove,
contributing to cell-cycle arrest.[19,20] While this
group is known to stabilize associations with GSK 3β-binding,
a similar binding mode may be approximated with alternative heterocycles,
which retain desirable, selective kinase-inhibiting effects in the
absence of DNA associations.[21] Because
of the differing routes of action of the β-carboline and ring
systems, replacement of the β-carboline may offer a promising
strategy for the development of a better lead molecule with activity
against cancer cells.
Differential Activation of G1 Phase Arrest
and Apoptosis by
Manzamine A (1)
To understand the mechanism of manzamine
A (1)-mediated cell growth inhibition, we analyzed the
cell-cycle distribution by flow cytometry in C33A, HeLa, SiHa, and
CaSki cell lines. At 24 h of treatment, C33A and HeLa cells showed
minimal differences in the cell-cycle distribution. However, there
was a significant decrease in cell population in G0/G1 at 48 (p = 0.043) and 72 (p = 0.0012) hours with
a corresponding increase in sub-G1 cell population as compared to
DMSO control (Figure A). C33A cells also showed a significant decrease in G2/M cell population
at 48 (p = 0.005) and 72 h (p =
0.02) as compared to HeLa cells. On the contrary, compound 1 induces a significant increase in cell population at G0/G1 phase
with a simultaneous decrease in S and G2/M phases in SiHa and CaSki
cells (Figure A).
Particularly at 4 μM concentration, the percentage of G0/G1
cell population in SiHa and CaSki increased to 1.2-fold (p = 0.001) and 1.4-fold (p = 0.011) at 24 h, and
1.2-fold (p = 0.03) and 1.5-fold (p = 0.006) at 48 h as compared to respective DMSO control.
Figure 3
Representation
of manzamine A (1) effect on cervical
cancer cells treated with 4 μM concentration. (A) Cell-cycle
regulation at three different time points: cells were stained with
PI, and analyzed by flow cytometry to estimate the amount of cells
in each phase of the cell cycle; and (B) apoptosis at 24 and 48 h:
cells were stained with Annexin-FITC and PI and analyzed by flow cytometry
to estimate the amount of apoptosis and necrotic cell population.
The values represent mean ± SEM. DMSO serves as control. The
significance level represents; *p < 0.05; **p < 0.001; ***p < 0001; and ns =
nonsignificant.
Representation
of manzamine A (1) effect on cervical
cancer cells treated with 4 μM concentration. (A) Cell-cycle
regulation at three different time points: cells were stained with
PI, and analyzed by flow cytometry to estimate the amount of cells
in each phase of the cell cycle; and (B) apoptosis at 24 and 48 h:
cells were stained with Annexin-FITC and PI and analyzed by flow cytometry
to estimate the amount of apoptosis and necrotic cell population.
The values represent mean ± SEM. DMSO serves as control. The
significance level represents; *p < 0.05; **p < 0.001; ***p < 0001; and ns =
nonsignificant.Since programmed cell death (apoptosis)
is a key mechanism by which
anticancer drugs kill cancer cells, we determined the apoptotic effect
of 1 on cervical cancer cells using annexin V and propidium
iodide (PI) staining. Forty-eight hours of treatment with compound 1 triggered significant increase in apoptosis in HeLa cells
(p = 0.005) as compared to C33A, SiHa, and CaSki
cells (Figure B).
However, C33A cells appear to be sensitive, as 1 induces
apoptosis (p = 0.002) and necrosis (p = 0.03) at 24 h with a further increase in late apoptosis (p = 0.03) and necrosis (p = 0.04) at 48
h. Given the sensitivity of C33A and HeLa cell lines to 1, an increase in apoptosis was expected. Overall, the percentage
of induced apoptotic cells (apoptosis + necrosis) at 4 μM was
higher at 48 h as compared to respective DMSO control in C33A (36.5
vs 17.3), HeLa (75.9 vs 19.3), SiHa (33.6 vs 6.4), and CaSki (23.2
vs 18.4), suggesting the role of 1 inducing apoptosis
in cervical cancer cells. CaSki cells were the least sensitive and
correspond to the IC50 values as in Figure .
Molecular Targets of Manzamine A (1)
HeLa, SiHa, and
CaSki cell lines represent the most common form of cervical cancerinfected by the HPV type 16 (SiHa and CaSki) and 18 (HeLa). Cervical
cancer is primarily aggravated by the sustained expression of HPV-derived
E6 and E7 oncogenes utilizing distinct mechanisms that affect cell-cycle
checkpoints. For instance, E6 promotes p53 degradation, while E7 is
associated with phosphorylation of retinoblastoma (Rb) proteins.[22,23] Both p53 and Rb are tumor suppressor genes and play a critical role
in maintaining cell-cycle regulation. Additionally, interaction of
cyclin D1 with Rb protein and their expression levels correlate positively
in association with tumorigenesis. Therefore, we sought to examine
the molecular targets of 1 leading to anticancer activity
in cervical cancer. Following treatment with the natural sponge product 1, we observed an increase in p53 and p21 protein levels and
inhibition of cyclin D1, total Rb, and phospho-Rb (Figure ) in SiHa and CaSki cells,
indicating that 1 may affect the regulation of both E6
and E7 oncogenes facilitating anticancer activities. HeLa cells showed
a marginal increase in p53 level, while the level of p21 remains unchanged.
On the contrary, HPV-negative C33A cells did not show any change in
p53 protein level, while the p21 protein level was not detectable
following 1 treatment. These data indicate a difference
in mechanism of 1 in HPV-positive and HPV-negative cell
lines. However, detailed mechanistic studies of 1 determining
anticancer effect are required to further substantiate these observations.
Figure 4
Effect
of manzamine A (1) on the cell-cycle regulatory
proteins in human cervical cancer cell lines. Following the overnight
attachment of 1 × 106 cells/well, the cells were treated
with manzamine A (1) at 2 and 4 μM concentrations
and incubated for 48 h. Cell lysates were prepared for protein analysis.
Effect
of manzamine A (1) on the cell-cycle regulatory
proteins in humancervical cancer cell lines. Following the overnight
attachment of 1 × 106 cells/well, the cells were treated
with manzamine A (1) at 2 and 4 μM concentrations
and incubated for 48 h. Cell lysates were prepared for protein analysis.Anticancer activity of sponge product 1 was further
evident from the inhibition of SIX1 protein, which is a homeodomain-containing
transcription factor expressed at high levels in a variety of cancers,
including cervical, colon, prostate, and breast cancers.[24−27] Overexpression of SIX1 leads to decreased expression of p53 as well
as aggressive clinical behavior of cancers and poor outcomes.[26−28] Interestingly, the E7 oncogene induces SIX1 expression in cervical
intraepithelial neoplasia and cervical cancer cells and accumulation
of cyclin D1 in tumor cells, resulting in tumorigenesis.[29,30] Our study demonstrated that 1 significantly inhibits
the SIX1 protein both in HPV-negative C33A cells and in HPV-positive
HeLa, SiHa, and CaSki cells (Figure ). These observations suggest that 1 induced
cytotoxicity in cervical cancer cells across this dose range is not
solely mediated by perturbing the E6/7 axis. Another possible mechanism
of 1 action is linked with the inhibition of glycogen
synthase kinase (GSK)-3β, a biological effect that is supported
by structural activity studies.[13,31] A recent study in colorectal
cancer showed that compound 1 induced cell-cycle arrest
in G0/G1 via inhibition of cyclin-dependent kinases and caspase-dependent
apoptotic cell death.[32] Furthermore, in
pancreatic cancer studies 1 has been shown to sensitize
pancreatic adenocarcinoma cells toward TRAIL-induced apoptosis, decreasing
cell dissociation and migration by inhibiting autophagy through prevention
of autophagosome turnover.[33,34] It is not currently
clear, however, whether 1 affects GSK3β and tumornecrosis factor (TNF)-dependent pathways in cervical cancer. While
the differences in the mechanism of 1 action could be
due to differential regulatory pathways in different cancer types,
we continued our efforts to determine the mechanism of anticancer
activity in cervical cancer.
Figure 5
Analyzing the effect of manzamine A (1) and apigenin
(a known inhibitor of CK2α protein) on a homeodomain containing
transcription factor SIX1 and CK2α in human cervical cancer
cell lines. Following the overnight attachment of 1 × 106 cells/well, the cells were treated with manzamine A (1) at 2 and 4 μM or apigenin at 10, 20, and 40 μM
concentrations and incubated for 48 h. Cell lysates were prepared
for protein analysis.
Analyzing the effect of manzamine A (1) and apigenin
(a known inhibitor of CK2α protein) on a homeodomain containing
transcription factor SIX1 and CK2α in humancervical cancer
cell lines. Following the overnight attachment of 1 × 106 cells/well, the cells were treated with manzamine A (1) at 2 and 4 μM or apigenin at 10, 20, and 40 μM
concentrations and incubated for 48 h. Cell lysates were prepared
for protein analysis.
Molecular Docking of Manzamine
A (1)
Molecular docking
assay is an effective tool to perform a preliminary evaluation of
possible bioactivity. Previous studies have indicated that, in addition
to E7 oncogene, SIX1 expression is regulated by protein kinase CK2.[29,35] SIX1 contains conserved CK2 sites at positions Thr-490, Ile-491,
Trp-492 and Asp-493. Inhibition of CK2 results in the diminished phosphorylation
of SIX1 and leads to a dose-dependent arrest at the G2/M boundary,
suggesting SIX1 as a plausible target of CK2. A molecular docking
study of 1 was performed on CK2 kinase alpha subunit
(CK2α) protein to evaluate the ligand–protein interactions
and binding affinity (Figure ). The binding affinity and interactions of manzamine A (1) to CK2α was compared to that of β-carboline,
ircinal A (5), 4,5,6,7-tetrabromobenzimidazole (TBB),
and apigenin. TBB and apigenin are inhibitors of CK2α, while
β-carboline and ircinal A (5) represent the partial
structures of manzamine A (1). The results showed 1 has a better binding affinity (−8.1 KCal/mol) than
the known CK2α inhibitor TBB (−7.4 KCal/mol). Both apigenin
(−9.1 KCal/mol) and β-carboline (−8.6 KCal/mol)
displayed better binding affinity than 1, while 5 (−5.1 KCal/mol) showed the most unfavorable binding
affinity. The comparison of binding space and interactions between
manzamine A (1) with TBB, apigenin, β-carboline,
and ircinal A (5) are shown in Figures and 7. The results
indicated that 1 shared similar binding interactions
and space with the known CK2α inhibitors, that is, TBB and apigenin.
The displayed favorable binding of 1 to CK2α is
due to the strong hydrophobic interactions in the binding pocket (Figure ). In support of
our in silico docking model, we examined the effect of manzamine A
(1) on CK2α protein corresponding to apigenin effect
on SIX1 protein level. We demonstrated that compound 1 decreased the level of CK2α protein that corresponds to SIX1
in C33A, SiHa, and CaSki cells (Figure ). Apigenin also decreased the proteins level of SIX1
and CK2α, however, at a much higher concertation (40 μM).
These data suggest that manzamine A (1) is almost 10
times more potent in inhibiting CK2α and SIX1 target proteins
as compared to the known inhibitor apigenin. Despite sensitivity of
HeLa cells to 1, we did not observe CK2α inhibition
indicating an additional signaling mechanism of cancer cell killing.
The study showed that β-carboline moiety of 1 is
able to extend deep into the binding pocket to form hydrophobic interactions
with similar amino acid residues (Met-163, Val-116, Ile-66, Val-53,
Val-45) as TBB and apigenin, while the ircinal moiety of 1 is located at the entrance of the binding pocket. Docking studies
on β-carboline and ircinal A (5) are in agreement
with 1 docking results, showing strong binding of β-carboline
at the binding pocket, while 5 exhibits poor binding
at the entrance of the binding pocket. These observations added another
potential application of 1 as CK2α inhibitor and
present a new avenue of study for manzamine A (1).
Figure 6
Comparison
of CK2α binding space for manzamine A (1) vs TBB
(A), apigenin (B), β-carboline (C), and ircinal A
(D). Manzamine A (1) structure is in gray color, while
the yellow structures represent known inhibitors.
Figure 7
Comparison
of CK2α binding interactions for manzamine A (1) vs TBB (A), apigenin (B), β-carboline(C), and ircinal
A (D). Manzamine A (1) structure is in gray color, while
the yellow structures represent known inhibitors.
Comparison
of CK2α binding space for manzamine A (1) vs TBB
(A), apigenin (B), β-carboline (C), and ircinal A
(D). Manzamine A (1) structure is in gray color, while
the yellow structures represent known inhibitors.Comparison
of CK2α binding interactions for manzamine A (1) vs TBB (A), apigenin (B), β-carboline(C), and ircinal
A (D). Manzamine A (1) structure is in gray color, while
the yellow structures represent known inhibitors.
Concluding Remarks
The manzamine class of marine alkaloids
is attractive in its potential for the development of novel therapeutics.
This group has been among the most extensively studied marine natural
products currently, being found in more than 16 species of Indo-Pacific
sponges distributed within distinct geographical regions.[36] The first of this class, manzamine A (1), from Haliclona(37) has demonstrated unprecedented potency against drug-resistant forms
of the malaria parasite (Plasmodium spp.),[38,39] showing greater potency and efficacy as compared to a number of
Food and Drug Administration (FDA)-approved antimalarial drugs, including
chloroquine. These molecules also show interesting activity as neuroprotective
and anti-inflammatory agents,[12−14] HIV/AIDS-associated opportunistic
infections,[12] and inhibition of cancer
proliferative and metastatic activity.[40] We showed that manzamine A (1) treatment leads to significant
decrease in the level of SIX1 and CK2α proteins along with the
regulation of cell-cycle related checkpoint proteins in cervical cancer
cell lines suggesting that 1 might be active in vivo
against cancers that express high levels of SIX1. In a direct comparison
to apigenin, an inhibitor of CK2α, this study demonstrated that 1 is ∼10 times more potent in inhibiting CK2α
and SIX1 proteins than apigenin. We have determined the oral toxicity
profile of 1 in a healthy rodent (rat) model (unpublished)
with a median lethal dose (LD50) between 200 and 300 mg/kg
body weight, comparable to that of acetaminophen (338 mg/kg orally)
in mice, while observed weight loss at high doses resulted in termination
of 1 for drug development by the Medicines for Malaria
Venture, whose primary target patient group is very young children.
It is anticipated that short-term weight loss would be less problematic
or would not necessarily offset the therapeutic gain in cancerpatients.While advantageous for natural product dereplication in its current
form, the MolN platform may benefit from the addition of applications
that marry existing networking capabilities with utilities for molecular
formula prediction and structural analysis, taking advantage of advanced
algorithms that simultaneously analyze human resources management
system (HRMS) and MS information contained within the data output.
Given that current workflows require data transfer and parallel analysis
within multiple software applications, an integrated platform such
as this would represent a powerful tool for streamlined and efficient
prioritization and deconvolution of molecular features with druglike
properties. Given the natural diversity of manzamine compounds, it
is possible that many more manzamine structures remain to be characterized
within this rich reservoir of sponge secondary metabolites in addition
to the potential to generate more useful molecules using rational
drug design.
Experimental Section
Cell Culture
Humancervical cancer cell lines C33A,
HeLa, SiHa, and CaSki were purchased from the American Type Culture
Collection (ATCC). Cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 100 U/ml of penicillin-streptomycin, and maintained
at 37 °C with 5% CO2 in a humidified incubator.
Generation of Normal Human Keratinocytes (HKc)
The
generation and processing of normal HKc from deidentified foreskin
tissue samples has previously been described in our studies[41] and was implemented with the following modifications:
Dispase was used in lieu of collagenase, and a trypsinization step
was added to release the epidermal cells. Briefly, to generate normal
HKc primary cultures, the foreskin tissue, free of subcutaneous tissue,
was placed in 10% Dispase in phosphate buffer saline (PBS) and incubated
overnight at 37 °C. The next day, the epidermis was separated
from the dermis and processed mechanically by shredding the tissue
into smaller pieces that were then treated with Trypsin/ethylenediaminetetraacetic
acid (EDTA) for 10 min at 37 °C. Following the addition of fetal
bovine serum (10%) to stop the trypsin action, cells were collected
by centrifugation and plated in keratinocytes serum free medium (KSFM).
Extraction and Isolation of Manzamine A (1)
Lipophilic
alkaloid extracts were previously prepared from the Indonesian sponge Acanthostrongylophora (collected from Manado Bay, Northern
Sulawesi, Indonesia, in 2003). Crude material was separated using
vacuum liquid chromatography, and 1 was purified by crystallization.
Purified 1 was then transformed into its hydrochloride
salt and recrystallized to reach high purity (>99%) and optimized
aqueous solubility as described previously.[12,15]
Cell Viability Assay
Cell viability was measured by
using Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega)
according to the manufacturer’s instructions. Briefly, 2 ×
104 cells were seeded in 96-well plates. The next day,
the cells were treated with different concentrations of manzamine
A (1) (0–40 μM) for 24, 48, and 72 h. Percent
viability was calculated using the formula: percent (%) viability
= 100 × (treatment/control). The IC50 value was calculated
from the dose-responsive sigmoid curve generated from % viability
using GrpaphPad Prism 7 software.
Cell-Growth Kinetics
Cervical cancer
cells (1 ×
106) or HKc (2 × 105) were plated in 100
mm tissue culture Petri dish or six-well plates. Following overnight
incubation, cells were treated with 2 or 4 μM concentrations
of manzamine A (1) derivatives for different time points
(24, 48, and 72 h). DMSO was used as control. The cell proliferation
activity was determined by cell counting under the microscope with
a hemocytometer using trypan blue staining.
Colony-Formation Assay
Cancer cell lines were seeded
at a density of 1 × 103 cells/ml in six-well plates.
Following overnight incubation, the cells were treated with manzamine
A (1) (2 and 4 μM) and incubated in a tissue culture
incubator at 37 °C with 5% CO2. After one week, the
developed cell colonies were fixed with 4% paraformaldehyde, stained
with 0.5% crystal violet, and were photographed.
Cell-Cycle
and Apoptosis Analysis
Cervical cancer cells
were seeded and treated with different concentrations of manzamine
A (1) as above. Following trypsinization, one part of
the cells was washed with PBS and fixed in chilled 70% ethanol on
ice for 30 min. Cells were treated with RNase A (1 mg/mL) at room
temperature for 30 min and stained with PI (20 μg/mL). Cell-cycle
distribution was analyzed by flow cytometry (Beckman Coulter Epics
Elite, Beckman). A minimum of 10 000 events was counted per
sample, and the data were analyzed using CXP software (Beckman Coulter)
for the proportions of cells in G0/G1, S, and G2/M phases of the cell
cycle. The second part of the cells was washed twice with PBS and
resuspended in the buffer containing Alexa Fluor conjugated-Annexin-V
and PI (Life Technologies). The double staining of the cells was analyzed
by flow cytometric analysis. A total of 10 000 cell events
were collected to analyze the extent of early, late apoptosis, or
necrosis from each sample with the percentages of bound annexin-V+/PI–, annexin V+/PI+, and annexin V–/PI+, respectively.
Protein Expression Analysis
C33A, HeLa, SiHa, and CaSki
cells were seeded at a density of 1 × 106 cells/100
mm Petri dish. The next day, the cells were treated with 2 or 4 μM
concentrations of manzamine A (1) or with 10, 20, or
40 μM concentrations with apigenin (Sigma) and incubated for
48 h. At the given time point, the cells were harvested by trypsinization,
washed with PBS, and lysed using radio-immunoprecipitation assay (RIPA)
buffer containing a cocktail of protease inhibitors (Sigma) to extract
protein. Following quantification by colorimetric assay (Bio-Rad),
an equal amount of protein was loaded on to sodium dodecyl sulfate
(SDS)-polyacrylamide gel and transferred to poly(vinylidene difluoride)
(PVDF) membrane, which was blocked in 5% nonfat dry milk in tris-buffered
saline with tween-20 (TBST) and incubated with primary antibody against
p53, p21, Cyclin D1, SIX1, GAPDH (Cell signaling) or CK2α (R&D
Systems) at a 1:500 dilution. For total CK2α, Rb, and pRb, the
blocking and antibody dilutions were made in 3% bovine serum albumin
(BSA). The membrane was washed with TBST and incubated with secondary
IgG HRP conjugate at 1:2000 dilution. The specific band of the protein
was visualized with chemiluminescence reagent exposed onto BioMax
Film (Kodak) and ChemoDoc-it[2] imager (UVP).
Molecular Networking
Alkaloid samples were resolubilized
in 100% methanol and analyzed on an online LC-ESI-MSMS system comprised
of an Agilent 1100 series pump/autosampler/diode array coupled to
a Bruker Impact II QqTOF. Samples (500 ng) were separated on a tetramethylsilane
(TMS)-end-capped C18 RPLC column (Kinetex 5 μM 100 Å, 250
× 4.6 mm column) with a gradient of 10–90% acetonitrile
+ 0.1% formic acid over 30 min (1 mL/min). Spectra were acquired within
the 150–2000 m/z mass range,
and the top three signals (300–1700 m/z) selected for MS2 fragmentation by collision
induced dissociation within a 2.0 Da window (50 eV), allowing for
dynamic exclusion after three observations (30 s). Raw data were uploaded
to the open-source Spectral Networking script at http://gnps.ucsd.edu(16) and filtered for features greater than or equal
to 2.5[3] counts. Spectra were merged employing
parent mass and MS/MS fragment ion tolerance threshold of 0.1 Da.
Only features with a minimum of five observations were retained in
the network. Edges were filtered for cosine scores above 0.60, retaining
nodes that appeared in each other’s respective top 10 most
similar nodes.[42,43] The resulting network was visualized
in Cytoscape 3.4.0.[44]
Nuclear Magnetic
Resonance (NMR)
The 1H
and 13C NMR spectra were recorded on a Bruker Nanobay 400
MHz (9.4 T) spectrometer in pyridine-d5. Chemical shifts are expressed in parts per million and were referenced
to residual solvent peaks (δH 7.22, 7.58, and 8.74; δC
123.9, 135.9, 150.4). Preparation-scale high-performance liquid chromatography
(HPLC) separation was performed using Waters 4000 Delta Prep system.
Molecular Docking
The MM2 energy-minimized three-dimensional
(3D) structure of ligands, that is, manzamine A (1),
β-carboline, ircinal A (5), 4,5,6,7-tetrabromobenzimidazole
(TBB), and apigenin were optimized using ChemBio3D Ultra version 12.0.
The crystal structure of Zea mays CK2 kinase alpha
subunit (CK2α) (PDB ID: 1J91) receptor protein was obtained from Protein
Data Bank (www.rcsb.org).[45] The ligands and receptor for molecular docking
experiments were prepared using AutoDockTools version 1.5.6, in which
the polar hydrogens were added to these structures.[46,47] The grit box parameter was set to cover the binding pocket in the
receptor, with x-dimension = 20; y-dimension = 20; z-dimension = 20; X-center = 21.774; Y-center = 8.022; and Z-center = 19.144. The grit box spacing was set as 1.0 Å.
The docking was performed using AutoDock Vina, and the binding affinity
values were measured. The outputs were visualized and analyzed using
BIOVIA Discovery Studio Visualizer version 17.2.0.
Statistical
Analysis
All experiments were performed
in duplicate and repeated three to four times with similar results.
All values are expressed as mean ± standard error of the mean
(SEM). Statistical analysis was performed using GraphPad Prism software
(GraphPad Software, Inc.). The value of p < 0.05
was considered statistically significant.
Authors: Esther A Guzmán; Jacob D Johnson; Patricia A Linley; Sarath E Gunasekera; Amy E Wright Journal: Invest New Drugs Date: 2010-03-30 Impact factor: 3.850
Authors: K A El Sayed; M Kelly; U A Kara; K K Ang; I Katsuyama; D C Dunbar; A A Khan; M T Hamann Journal: J Am Chem Soc Date: 2001-03-07 Impact factor: 15.419
Authors: Susanne K Kjaer; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; F Xavier Bosch; Joakim Dillner; Elmar A Joura; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Roger Maansson; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Alfred Saah; Eliav Barr; Richard M Haupt Journal: Cancer Prev Res (Phila) Date: 2009-09-29
Authors: Jonathan A Panggabean; Sya'ban P Adiguna; Tutik Murniasih; Siti I Rahmawati; Asep Bayu; Masteria Y Putra Journal: Rev Bras Farmacogn Date: 2022-01-07 Impact factor: 2.464
Authors: Alejandro M S Mayer; Mary L Hall; Joseph Lach; Jonathan Clifford; Kevin Chandrasena; Caitlin Canton; Maria Kontoyianni; Yeun-Mun Choo; Dev Karan; Mark T Hamann Journal: Mar Drugs Date: 2021-09-07 Impact factor: 5.118